- 专利标题: Dual molecular delivery of oligonucleotides and peptide containing conjugates
-
申请号: US15974135申请日: 2018-05-08
-
公开(公告)号: US10532068B2公开(公告)日: 2020-01-14
- 发明人: Steven L. Colletti , Thomas J. Tucker , David M. Tellers , Boyoung Kim , Rob Burke , Kathleen B. Calati , Matthew G. Stanton , Rubina G. Parmar , Jeffrey G. Aaronson , Weimin Wang
- 申请人: Merck Sharp & Dohme Corp.
- 申请人地址: US NJ Rahway
- 专利权人: Merck Sharp & Dohme Corp.
- 当前专利权人: Merck Sharp & Dohme Corp.
- 当前专利权人地址: US NJ Rahway
- 代理商 Yong Zhao; Anna L. Cocuzzo
- 主分类号: C12N15/87
- IPC分类号: C12N15/87 ; A61K31/713 ; A61K38/10 ; A61K38/16 ; C12N15/11 ; C12N15/113 ; A61K31/7125
摘要:
Disclosed herein is a method for inhibiting expression of a gene of a subject comprising administering (1) a composition comprising R-(L)a-(G)b; wherein R is an oligonucleotide selected from the group consisting of DNA, RNA, siRNA, and microRNA; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; each of a and b is independently 0, 1, 2, 3 or 4; and (2) a composition comprising (P)c-(L)d-(G)e; wherein P is a peptide and each occurrence of P is independently selected from Table 2; L is a linker and each occurrence of L is independently selected from Table 3; G is a targeting ligand and each occurrence of G is independently selected from Table 4; d is 0, 1, 2, 3, 4, 5 or 6; and each of c and e is independently 1, 2, 3, 4, 5 or 6. Compositions in (1) and (2) can be co-administered or sequentially administered.
公开/授权文献
信息查询
IPC分类: